Background. Iron deficiency is a major cause of anemia and the most prevalent nutrient deficiency among pregnant women in developing countries. The use of iron and folic acid supplements to treat and prevent irondeficiency anemia has limited effectiveness, mainly due to poor adherence. Home fortification with a micronutrient powder for pregnant women may be an effective and acceptable alternative to traditional drug models.
Background
Iron is an essential mineral for human development and physiological function. Iron deficiency, in particular iron-deficiency anemia, remains one of the most common nutritional deficiencies worldwide [1] . Children aged 6 months through 5 years and women of childbearing age, in particular women during pregnancy, are the most vulnerable groups [2] . During pregnancy, iron is critical for the health of both the mother and the child. Iron deficiency during pregnancy is associated with several adverse outcomes, including an increased risk of maternal morbidity and mortality, preterm delivery, and low birthweight [3] [4] [5] . The impact of anemia on premature birth and low birthweight is a significant health burden, since preterm infants are more likely to have perinatal complications, be growth stunted, and have low stores of iron and other essential micronutrients [3, 6] . If left untreated, iron-deficiency anemia in children has significant negative consequences on cognitive performance and physical growth [2] .
The major cause of anemia in pregnancy is iron deficiency, which is preventable. It is estimated that 56% of pregnant women in developing countries and 18% of pregnant women in industrialized countries are anemic [7] . The prevalence of anemia during pregnancy in South Asian countries is among the highest in the world. A study conducted in rural Bangladesh reported a 54% prevalence of anemia among pregnant women during the second trimester [6] . Similar high rates of anemia have been reported among lower-and middle-class pregnant women in Dhaka * . Although a number of national programs have been implemented attempting to address this problem, continuing high rates of anemia among pregnant women suggest that traditional strategies such as iron-folic acid (IFA) tablets are not effective [8] . This limited effectiveness may be attributable to inadequate supply, low coverage, and/ or poor adherence
In order to address poor adherence to standard iron drops in young children, micronutrient Sprinkles, a single-serving sachet containing a blend of micronutrients in powder form, was developed. Powdered micronutrient supplements can be easily incorporated into foods prepared in the home. Several clinical trials have demonstrated the efficacy of micronutrient powders in lowering the burden of anemia in children in the developing world [9] [10] [11] [12] . However, no study to date has examined the efficacy of this intervention against anemia throughout pregnancy. In the clusterrandomized trial reported here, our objective was to determine whether home fortification with a micronutrient powder for pregnancy (MNP-P) is at least as efficacious as IFA tablets for improving hemoglobin concentration in pregnant women.
Methods

Study setting
A cluster-randomized noninferiority trial was carried out in the subdistrict of Kaliganj in central Bangladesh. This is a densely populated rural area that relies primarily on agricultural labor. Participants were recruited from 42 community-based Antenatal Care Centres operated by BRAC (formerly known as the Bangladesh Rural Advancement Committee), a large nongovernmental organization founded in Bangladesh in 1972.
Participant selection
All pregnant women who received services at one of the Antenatal Care Centres and were between 14 and 22 weeks of gestation were asked to join the study. Gestational age was approximated by using the woman's recall of her last menstrual period. If the number of * Vanneste A. Routine versus selective iron supplementation in pregnant women. Policies for Bangladesh. Dhaka: International Centre for Diarrhoeal Disease Research, Bangladesh, 1994 participants enrolled from one Antenatal Care Centre did not meet the sample size requirements, the study team returned to the centre the following month and repeated the recruitment process. For logistical reasons, we limited our recruitment phase to the first 5 months of the study period, which started in October 2005 and ended in March 2006. Women did not meet the eligibility criteria if they were severely anemic (hemoglobin < 70 g/L), had a hemoglobin concentration greater than 140 g/L, were at more than 22 weeks of gestation, or were already taking iron supplements prior to the start of the study. The primary reason for declining to participate in the study was unwillingness to provide a blood sample for hemoglobin assessment.
A total of 779 pregnant women from 42 clusters were identified ( fig. 1 ). Out of this population, 478 women met the eligibility criteria and were randomized, at the cluster level, to the MNP-P group (21 clusters, n = 243) or the IFA tablet group (21 clusters, n = 235). Each cluster consisted of approximately 300 households, and the number of women per cluster ranged from 3 to 26. The primary reasons for exclusion at baseline were gestational age greater than 22 weeks (15.8%), recent use of iron supplements (11.3%), pregnancy loss (4.4%), and planned move out of the study area (2.2%). Two women were excluded because they had severe anemia (hemoglobin < 70 g/L), and 12 were excluded because they had hemoglobin levels above 140 g/L ( fig. 1) .
Sample size and power
The sample size estimation was based on the primary outcome, mean hemoglobin concentration at 24, 28, and 32 weeks of gestation. It was assumed that the mean hemoglobin level in the IFA group would be 125 g/L, with a between-subject standard deviation of 15 g/L [13] . The objective of this noninferiority trial was to establish with 95% confidence that the mean hemoglobin level in the MNP-P group was no more than 5 g/L below that in the IFA group. Using a one-tailed alpha of 0.05 and an intraclass correlation coefficient (ICC) of 0.03, the total required sample size was estimated at 352. Based on previous research, loss to follow-up in this population of pregnant women was estimated to be 35% [6] . Therefore, a total of 12 women from each Antenatal Care Centre was the target number to recruit.
Intervention
A single Antenatal Care Centre typically serves one village or population of approximately 300 households. Each Antenatal Care Centre was defined as a cluster, and each cluster was randomly allocated to receive either MNP-P (60 mg of elemental iron, 400 μg of folic acid, 30 mg of vitamin C, and 5 mg of zinc) or IFA tablets (60 mg of elemental iron and 400 μg of folic acid). The iron dose corresponded to recommendations for areas in which the prevalence of anemia is above 40%, and the dose of folic acid administered was based on the amount of synthetic folic acid recommended for prevention of neural tube defects [2] . Both interventions were administered daily starting at the first study visit and lasting until 32 weeks of gestation. Those assigned to the MNP-P group were instructed to sprinkle the full contents of a package into any semisolid or semiliquid food when the food was at room temperature.
Data collection
During the baseline assessment, a questionnaire was administered to collect socioeconomic, demographic, and health data. Anthropometric measurements, including weight and height, were also completed during the baseline visit. Hemoglobin concentration was determined at 24, 28, and 32 weeks of gestation with a portable hemoglobin photometer (HemoCue®) by trained technicians using standardized techniques. The fieldworkers visited the participants at 2-week intervals after the baseline visit. During these visits, the fieldworkers assessed adherence by recording the number of empty and full MNP-P sachets remaining or the number of unused IFA tablets and asking specific questions about the sharing and general use of the supplements. Adherence was defined as the ratio of the number of tablets or sachets consumed to the total recommended during a specific period of time. At each visit, the fieldworkers also provided educational support with the use of a flip chart to maximize adherence to the interventions. 
Data processing and analysis
Univariate analyses of selected variables were conducted with SPSSWIN, version 11.0. Descriptive analyses were used to compare the intervention groups with respect to baseline demographic and anthropometric characteristics. Changes in hemoglobin concentration from baseline were compared across groups at 24, 28, and 32 weeks of gestation using a linear mixed effects regression model to account for clustering. Treatment group, baseline hemoglobin, and baseline postconceptual age were designated as fixed effects, and subject (nested within Antenatal Care Centre) was designated as a random effect. The model was further adjusted for the effect of potential confounders, including education, body mass index (BMI), and adherence. These analyses were conducted with Stata, version 9.1. Noninferiority of the MNP-P treatment compared with IFA tablets (for the effect on hemoglobin concentration) was concluded if the lower bound of the one-sided 95% confidence interval for the treatment effect was above the -5 g/L margin, with significance level α = 0.05. All analyses were conducted on an intention-to-treat basis.
Ethical approval and consent
Ethical approval was obtained from the Hospital for Sick Children (Toronto, Canada) and the Bangladesh Medical Research Council (BMRC). Informed and signed consent was obtained individually from the participants in the study, and all data were coded to remove identifying information and secure confidentiality.
Results
As depicted in figure 1 , the loss to follow-up at 32 weeks was similar between groups (14.8% vs 15.7% in the MNP-P and IFA groups, respectively); however, the proportion of these women who dropped out due to "refusal to participate" was higher in the MNP-P group (8.2%) than in the IFA group (1.7%). Those who were "not available/absent" accounted for 2.9% and 6.8% of dropouts in the MNP-P and IFA groups, respectively. The primary reasons for a woman's being not available or absent for a follow-up visit were traveling (e.g., to her mother's home) or moving to another village. A comparison of baseline demographic, anthropometric, and reproductive characteristics in the MNP-P and IFA groups is presented in table 1. The mean age of the women in both groups was 22 years (range, 14 to 46 years), and all were in their second trimester of pregnancy (14 to 22 weeks of gestation). Sixty percent of the households were functionally landless, and 88% of the women had attended at least 1 year of school. Fortyfive percent of the women were anemic at baseline, of whom half were moderately anemic (hemoglobin 70 to 99 g/L) (table 1). By 32 weeks of gestation, the prevalence of mild anemia had increased by 3% in the MNP-P group and 7% in the IFA group, whereas the proportion of those with moderate anemia was 4% and 7% lower in the MNP-P and IFA groups, respectively (table 2). With the exception of one subject in the MNP-P group at 24 weeks, none of the women in either group developed severe anemia (hemoglobin < 70 g/L) during the intervention period (data not shown). The overall mean hemoglobin levels did not differ statistically between groups throughout the intervention period (table 3) . Among women who were anemic at recruitment, mean hemoglobin at 32 weeks was significantly higher in the IFA group than in the MNP-P group, although both groups demonstrated improvements in hemoglobin concentration from baseline (7.6 g/L in the MNP-P group and 12.3 g/L in the IFA group) (table 3). In the mixed effects analysis, the effect of MNP-P on hemoglobin concentration was not found to be inferior to that of IFA tablets in terms of the overall group effect or by each time point (group*time effect). These findings suggest that the relative efficacy of MNP-P and IFA tablets was similar in this population (table 4). Mean ± SD adherence at 32 weeks of gestation was 57.5% ± 22.5% in the MNP-P group and 76.0% ± 13.7% in the IFA group. The adjusted mixed-effects analysis revealed a significant negative association for adherence in the MNP-P group, although percent adherence was positively correlated with mean hemoglobin concentrations in both groups (table 4). This correlation was consistent among both women who were anemic and those who were nonanemic at baseline ( fig. 2) . There was no documentation of sharing, selling, or other use of the two supplements. 
Discussion
In the present study, the relative efficacy of two different models of iron supplementation-a powdered multiple micronutrient fortificant and an iron-folic acid tablet-was evaluated in pregnant women in rural Bangladesh. After a 10-to 14-week intervention, the mean hemoglobin levels among those who received iron in powdered form did not differ from that among women who received IFA tablets. The efficacy of the micronutrient powder was also statistically not inferior to that of the IFA tablets in treating and preventing anemia in this population. Other studies in pregnant women in developing countries have reported similar findings of the efficacy of food-based micronutrient interventions in treating or preventing anemia. Two studies comparing micronutrient-fortified beverages with unfortified preparations demonstrated improved iron status among Chilean and Tanzanian pregnant women [14, 15] . Gai et al. compared a food-based nutrient powder with multiple-micronutrient tablets (containing iron, folic acid, calcium, and vitamins A and D) in pregnant women and found that hemoglobin concentrations remained within the normal range and did not differ statistically between groups [16] .
The baseline prevalence of anemia among the study population of pregnant women was approximately 45%. This is similar to the findings from a national anemia prevalence survey conducted in 2003 by the Bangladesh Bureau of Statistics [17] , although it is higher than 2004 estimates from the Nutritional Surveillance Project [18] . In the present study, women in the MNP-P group who were anemic at baseline had positive mean changes in hemoglobin concentration that were smaller in magnitude than those for women in the IFA group. Generally poorer hemoglobin responses in the MNP-P group may have been due to differences in the absorption of iron from micronutrient powders versus IFA tablets. In a randomized trial comparing the bioavailability of iron and folic acid from a micronutrient powder added to food with their bioavailability from a traditional tablet among healthy pregnant women (24 to 32 weeks of gestation), Hartman-Craven et al. reported significantly lower iron absorption in the MNP group, as defined by changes in serum iron over 8 hours from baseline [19] . Although these results suggest a possible biological explanation for differences in iron absorption between iron tablets and powders, they are also difficult to apply to our findings for two reasons: firstly, the form of iron in the micronutrient powder used by Hartman-Craven et al. was ferric pyrophosphate, whereas the form of iron used in the present study was ferrous fumarate. Ferric pyrophosphate is significantly less bioavailable, and may be more influenced by the food matrix, than more soluble forms of iron, such as ferrous fumarate or ferrous sulfate [20, 21] .
Secondly, the participants in the Hartman-Craven trial were nonanemic at baseline, whereas almost half of the subjects in the present study were anemic at baseline (hemoglobin < 110 g/L). It is suggested in the literature that iron-deficiency anemia will promote increased absorption of dietary iron [22] . Although a biochemical measure of body iron stores (such as serum ferritin) was not obtained in the present study, it may be assumed that iron deficiency was a primary cause of anemia among these pregnant women [23, 24] . Therefore, the relative bioavailability of iron from MNP-P may not have been a major contributing factor to the difference in hemoglobin response between groups. An alternative explanation may be associated with the timing of supplementation initiation. In a meta-analysis of 12 studies from developing countries comparing antenatal supplements of multiple micronutrients with iron and folic acid, Margetts et al. suggested that there is a potential for interaction between the gestational age at which supplements commence and the nutritional status of the mother at conception on the impact of the supplementation [25] . It is possible that the mean hemoglobin levels in our study population of pregnant women would have been more improved if the intervention had started at an earlier stage of pregnancy and/or continued beyond 32 weeks of gestation.
In addition to supplement timing, differences in adherence to the intervention between the groups may partly explain the heterogeneity in biological response. As mentioned above, low adherence to iron tablets is a common observation in studies of pregnant women and is often referred to as a significant contributor to the reduced efficacy of iron supplementation. In the present study, the mean adherence at 32 weeks of gestation in the MNP-P group (57.5%) was similar to that reported by Khambalia et al. (57.7%), who investigated periconceptional use of micronutrient powders (containing iron) in Bangladeshi women [26] , but much lower than that reported by Christian et al. in a study of micronutrient tablets in Nepalese women (86% to 88%) [27] . One of the obvious differences between these studies is the mode of iron delivery: micronutrient powders are consumed after mixing them with food and tablets are not. As indicated in previous work by our group and others, the type of food that micronutrient powders are mixed with may affect the acceptability of the product and hence the desire to adhere to the dosing regimen [28] . In rural areas of Bangladesh, the primary staple food is rice, which tends not to blend well with powdered micronutrients, which cause it to become gritty or sour-tasting. In the present study, we conducted focus group discussions to explore the reasons for nonadherence. Nonadherent women in the MNP-P group expressed concern that adding Sprinkles to their daily food would worsen the nausea associated with pregnancy. However, a few women also mentioned that Sprinkles increased their appetite. Given that food was generally scarce, increased appetite was not a positive attribute of the intervention. It is possible that the above-mentioned factors affecting the acceptability of the MNP intervention, as well as a potential reluctance among the women to try an intervention that is novel in Bangladesh, where IFA tablets are routinely used, may have played a role in the reduced adherence and increased dropout rates observed in the MNP-P group. It is important to note, however, the positive correlation between adherence to the intervention and hemoglobin concentration that was observed in this trial. The association between adherence to food-based iron supplementation with micronutrient powders and hemoglobin concentrations in pregnant Bangladeshi women was also assessed by Khambalia et al., who found that each 1% increase in adherence to the micronutrient powder was associated with a 10 g/L increase in hemoglobin from baseline [26] .
Overall, our findings suggest that despite lower adherence, the relative efficacy of MNP-P and IFA tablets was similar when they were started in the second trimester of pregnancy. The interpretation of our results is limited to "relative" comparisons, since the randomized design did not include a nonintervention group (placebo control). If we had included a nonintervention group (which would have been unethical), it is likely that the impact of the two interventions would have been more clinically robust. Given the limited number of studies on MNP use during pregnancy, it is also difficult to assess the effectiveness and feasibility of this approach in a program setting. In fact, recently published World Health Organization (WHO) guidelines on the use of MNPs during pregnancy recommended against this intervention as an alternative to iron and folic acid supplements due to a lack of evidence on its potential benefits and harms [29] . The guidelines also stated, however, that current supplementation and mass food fortification approaches do not always work because of difficulties in implementation or reaching target populations [29] . There has been growing interest in alternative strategies for providing micronutrients to pregnant women in low-and middle-income countries, and WHO has recommended that future research be conducted to evaluate the effectiveness of MNPs as one such strategy. Considering the findings from the present study, we suggest that further research on factors related to MNP adherence that addresses culture-specific food preferences would be of particular benefit; however, it is possible that simply having a choice between tablets or MNP-P might improve overall adherence to iron and folic acid interventions among pregnant women.
